PL3962942T3 - Preparat przeciwciała anty-il-6 - Google Patents
Preparat przeciwciała anty-il-6Info
- Publication number
- PL3962942T3 PL3962942T3 PL20728590.9T PL20728590T PL3962942T3 PL 3962942 T3 PL3962942 T3 PL 3962942T3 PL 20728590 T PL20728590 T PL 20728590T PL 3962942 T3 PL3962942 T3 PL 3962942T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody preparation
- antibody
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841662P | 2019-05-01 | 2019-05-01 | |
| EP19181345 | 2019-06-19 | ||
| PCT/US2020/030865 WO2020223565A1 (en) | 2019-05-01 | 2020-04-30 | Anti-il-6 antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3962942T3 true PL3962942T3 (pl) | 2026-02-16 |
Family
ID=70857238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20728590.9T PL3962942T3 (pl) | 2019-05-01 | 2020-04-30 | Preparat przeciwciała anty-il-6 |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP4631523A3 (pl) |
| JP (3) | JP7701273B2 (pl) |
| ES (1) | ES3055418T3 (pl) |
| HR (1) | HRP20251529T1 (pl) |
| MA (1) | MA55809B1 (pl) |
| PL (1) | PL3962942T3 (pl) |
| RS (1) | RS67540B1 (pl) |
| WO (1) | WO2020223565A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856135A (en) | 1993-05-31 | 1999-01-05 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human antibody to human interleukin-6 |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| RU2318829C2 (ru) | 2001-11-14 | 2008-03-10 | Сентокор, Инк. | Антитела против il-6, композиции, способы и применение |
| AU2003261787B2 (en) | 2002-08-30 | 2008-11-06 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of the antibody |
| PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
| MX2007014564A (es) | 2005-05-20 | 2008-02-07 | Ablynx Nv | Anticuerpos de vhh de dominio unico contra el factor de von willebrand. |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| CA2749200A1 (en) | 2009-01-29 | 2010-08-05 | Michael Bowen | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| CN104768578A (zh) * | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| CA3119498A1 (en) | 2015-07-31 | 2017-02-09 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| EP3419599A4 (en) * | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
| TWI716668B (zh) | 2017-02-01 | 2021-01-21 | 耶魯大學 | 心臟衰竭及心腎症候群之精準治療 |
| MX2020006882A (es) | 2018-01-05 | 2020-09-07 | Novo Nordisk As | Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion. |
-
2020
- 2020-04-30 EP EP25187279.2A patent/EP4631523A3/en active Pending
- 2020-04-30 JP JP2021564800A patent/JP7701273B2/ja active Active
- 2020-04-30 EP EP20728590.9A patent/EP3962942B1/en active Active
- 2020-04-30 MA MA55809A patent/MA55809B1/fr unknown
- 2020-04-30 PL PL20728590.9T patent/PL3962942T3/pl unknown
- 2020-04-30 ES ES20728590T patent/ES3055418T3/es active Active
- 2020-04-30 EP EP25169130.9A patent/EP4591885A3/en active Pending
- 2020-04-30 RS RS20251287A patent/RS67540B1/sr unknown
- 2020-04-30 WO PCT/US2020/030865 patent/WO2020223565A1/en not_active Ceased
- 2020-04-30 HR HRP20251529TT patent/HRP20251529T1/hr unknown
-
2025
- 2025-04-24 JP JP2025072422A patent/JP7755766B2/ja active Active
- 2025-08-13 JP JP2025134815A patent/JP2025166156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA55809B1 (fr) | 2025-12-31 |
| EP4631523A3 (en) | 2025-12-31 |
| ES3055418T3 (en) | 2026-02-11 |
| JP2025166156A (ja) | 2025-11-05 |
| EP3962942C0 (en) | 2025-10-22 |
| WO2020223565A1 (en) | 2020-11-05 |
| EP4591885A2 (en) | 2025-07-30 |
| EP4591885A3 (en) | 2025-11-19 |
| JP7701273B2 (ja) | 2025-07-01 |
| JP2025114623A (ja) | 2025-08-05 |
| MA55809A (fr) | 2022-03-09 |
| EP3962942B1 (en) | 2025-10-22 |
| EP4631523A2 (en) | 2025-10-15 |
| EP3962942A1 (en) | 2022-03-09 |
| JP7755766B2 (ja) | 2025-10-16 |
| HRP20251529T1 (hr) | 2026-01-16 |
| JP2022531331A (ja) | 2022-07-06 |
| RS67540B1 (sr) | 2026-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102763158B9 (ko) | 최적화된 항tl1a 항체 | |
| EP4442278C0 (en) | HUMANIZED ANTIBODIES DIRECTED AGAINST C-KIT | |
| IL289354A (en) | Anti-cd154 antibodies and uses thereof | |
| EP3822289A4 (en) | ANTI-SIRP-ALPHA ANTIBODIES | |
| EP3797122A4 (en) | Anti-ror antibody constructs | |
| EP3794041C0 (en) | ANTI-MUC1 ANTIBODIES | |
| MA52212A (fr) | Anticorps multivalent | |
| EP3849598A4 (en) | Anti-trem-2 agonist antibodies | |
| EP3950061A4 (en) | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | |
| EP3941944A4 (en) | Claudin-6 bispecific antibodies | |
| PL3449940T3 (pl) | Preparat zawierający przeciwciała | |
| EP3589648A4 (en) | MONOCLONAL ANTI-RSV ANTIBODY FORMULATION | |
| IL281717A (en) | Antibody formulation | |
| EP3763743A4 (en) | BISPECIFIC ANTIBODY | |
| EP4081547A4 (en) | Novel anti-fgfr2b antibodies | |
| CR20230573A (es) | ANTICUERPOS ANTI-SIRP-alfa | |
| EP3806903A4 (en) | CD79A CHIMERIC ANTIGEN RECEPTORS | |
| DK4214240T3 (da) | Anti-ccr8-antistoffer | |
| HUE061610T2 (hu) | Készítmény | |
| IL282813A (en) | Antibody formulation | |
| EP3615678C0 (en) | ANTIBODY SELECTION METHOD | |
| IL281976A (en) | Anti-fgfr2 antibody formulations | |
| IL286024A (en) | Stabilized formulations containing anti-il-33 antibodies | |
| IL283886A (en) | Antibody formulations | |
| IL289252A (en) | Ep2 antagonist |